Form 4 for WST West Pharmaceutical Services
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-17 · accession 0000105770-26-000016 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-19 | 2026-02-17 | WST | Favorite Annette F | SVP, Chief HR Off | A - Grant | $0.00 | +441.96 | 17.4K | +3% | $0 |
| D | 2026-02-19 | 2026-02-18 | WST | Favorite Annette F | SVP, Chief HR Off | M - OptEx | — | +135.49 | 17.4K | +0.8% | — |
| DM | 2026-02-19 | 2026-02-17+ | WST | Favorite Annette F | SVP, Chief HR Off | F - Tax | $244.16 | -186.20 | 17.3K | -1% | -$45.5K |
| D | 2026-02-19 | 2026-02-18 | WST | Favorite Annette F | SVP, Chief HR Off | M - OptEx | $0.00 | -135.49 | 408.49 | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-17 | A | A | 441.96 | $0.00 | 17,425.20 | D | — | — | (F1) These shares result from performance stock units (PSUs) which vested at the end of the respective 2023-2025 PSU performance period and were payable on the transaction date shown. |
| 2 | Common | Common Stock | 2026-02-18 | M | A | 135.49 | — | 17,410.25 | D | — | — | (F2) Restricted stock units convert into common stock on a one-for-one basis. |
| 3 | Common | Common Stock | 2026-02-18 | F | D | 35.76 | $248.26 | 17,374.49 | D | — | — | |
| 4 | Common | Common Stock | 2026-02-17 | F | D | 150.44 | $243.19 | 17,274.76 | D | — | — | |
| 5 | Derivative | Rst. Stock Unit | 2026-02-18 | M | D | 135.49 | $0.00 | 408.49 | D | — · — to — | 135.49 Common Stock | (F2) Restricted stock units convert into common stock on a one-for-one basis. (F3) On February 18, 2025, the reporting person was granted 542 restricted stock units, vesting in four equal annual installments (plus dividend equivalents). |